Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Hormone Receptor Positive Tumor
Interventions: DRUG: Durvalumab|DRUG: Anastrozole 1mg|DRUG: Letrozole 2.5mg|DRUG: Exemestane 25 MG
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: AstraZeneca